← Back

Shandong Xinhua Pharmaceutical Co Ltd

Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand, as well as contract manufacturing services for active pharmaceutical ingredients, pharmaceutical intermediates, OTC products, and generics. The company also provides ibuprofen bulk pharmaceutical products and prepared Chinese herbal medicine for decoction, along with traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, and medical toxic drugs. In addition, it offers raw materials and intermediates, internet data services, internet sales, and internet information services for pharmaceuticals and medical devices, veterinary drugs and fodders, steroid system APIs and intermediates, and chemical raw materials. The company also produces and sells chemical products, exports and imports goods and technologies, designs medical projects, and engages in property management, nonresidential real estate and housing leasing, certification and import-export business, installation and testing of chemical equipment, manufacture of mechanical and electrical equipment and nonstandard equipment, production of hardware and electrical equipment, electrical installations equipment and manufacture, and sale of controller switching equipment. Founded in 1943, it is based in Zibo, the People's Republic of China.

Country
Price · split & dividend adjusted
News & notes moving 000756.CS
000756.CS▲

Xinhua Pharmaceutical's Azithromycin Tablets Pass Consistency Evaluation

Shandong Xinhua Pharmaceutical Company announced that its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Company's azithromycin tablets, at a strength of 0.25 grams, have passed the generic drug quality and efficacy consistency evaluation by the National Medical Products Administration, and obtained the Drug Supplementary Application Approval Notice. This product is a Class A item under national medical insurance, indicated for a variety of infectious diseases, with sales of approximately 670 million yuan in Chinese public medical institutions in 2025. The company submitted the application materials in September 2025 and received approval in August 2026. This move is expected to enhance market competitiveness, but drug sales remain subject to industry policies and other factors.
000756.CS ▲
Jiemian·19dRead more →
000756.CS▼

Xinhua Pharmaceutical's 2026 interim net profit was 149 million yuan, down 33.35% year-on-year

Xinhua Pharmaceutical released its 2026 interim report. Total operating revenue was 4.358 billion yuan, down 6.06% year-on-year. Net profit attributable to the parent company was 149 million yuan, down 33.35% year-on-year. Net cash inflow from operating activities was 161 million yuan, down 31.40% year-on-year. The company's asset-liability ratio was 39.32%, gross margin was 19.16%, ROE was 2.83%, and diluted earnings per share was 0.21 yuan. Total asset turnover was 0.48 times, and inventory turnover was 2.70 times. The number of shareholders was 79,900, and the top ten shareholders held 63.62% of the total share capital.
000756.CS ▼
Jiemian·24dRead more →
000756.CS▲2

Xinhua Pharmaceutical Receives Drug Registration Certificate for Dapagliflozin Tablets

Xinhua Pharmaceutical announced that the company has received the Drug Registration Certificate for Dapagliflozin Tablets approved and issued by the National Medical Products Administration. The drug is in tablet form, with specifications of 10 mg and 5 mg, registered as a Category 4 chemical drug. It is indicated for adult patients with type 2 diabetes and adult patients with heart failure, and is classified as a Category B drug under national medical insurance. In 2025, sales of dapagliflozin tablets in China's public medical institutions reached approximately 11.4 billion yuan. This approval will further enrich the company's product portfolio and help enhance its market competitiveness.
000756.CS ▲
CLS·28dRead more →
© 2026 MarketDXAsset